BMRN recent upgrade short notes
Baird raises price target to $36.00. Baird analyst says, "Incrementally positive, raising price target after hosting an investor dinner with management this week. We are increasingly optimistic about this company’s pipeline with two un-modeled opportunities (PEG-PAL and BMN701 for Pompe disease) both poised for significant 2012 news. Coupling this with GALNS Phase III data on track for 2H12 and a steady-growth base business, we think new money would be well placed in this stock at current levels."
BioMarin initiated with an Outperform at RBC Capital - Target $36
BioMarin shares should appreciate through 2012, says Collins Stewart. After meeting with management, Collins Stewart believes BioMarin's pipeline catalysts should drive shares higher through 2012. The firm keeps a Buy rating on the stock with a $33 price target.
